A Dissertation Submitted for Ph.D. Degree in Pharmaceutical Biotechnology
Total Page:16
File Type:pdf, Size:1020Kb
Faculty of Pharmacy Tabriz University of Medical Sciences A Dissertation submitted for Ph.D. degree in Pharmaceutical Biotechnology Entitled: Cloning and sequencing of riboswitches of Alishewanella tabrizica strain RCRI4 and comparative studies on similar riboswitches in other bacteria By: Elnaz Mehdizadeh Aghdam Supervisors: Dr Mohammad Saeid Hejazi Dr Abolfazl Barzegar Advisor: Dr Jörg S. Hartig September 1026 Thesis No: 00 Clarification and Copyright Declaration I hereby declare that I am the sole author of this thesis. I take full responsibility of this work and declare that the results of this study are original and based on my personal work. All scientific materials used in this thesis are fully referenced. All rights are transferred to Faculty of pharmacy, Tabriz University of Medical sciences. The Faculty of pharmacy is authorized to lend or reproduce this thesis, in total or in part. Professors’ names: Dr. Mohammad Saeid Hejazi; Dr Abolfazl Barzegar Signature: Name: Elnaz Mehdizadeh Aghdam Student No: 0020210102 Date: Signature: I would like to dedicate this thesis to my dear husband Dr Hamid Reza Heidari For his endless patience, kindness and love Acknowledgments I would like to express my deepest acknowledgments to my supervisor, Prof. Mohammad Saeid Hejazi, for the patient guidance, encouragement and advice he has provided throughout my time as his student. I have been extremely lucky to have a supervisor who cared so much about my work, and who responded to my questions and queries so promptly. I believe he has been more than a supervisor to me, as he has guided me patiently and constantly all through my academic life and I am and will be grateful to him for the rest of my life. My special thanks also go to my second supervisor Dr Abolfazl Barzegar for all the incredible opportunities he made for me and his constant kind support and motivation. I would like to thank Prof. Jörg Hartig for his extremely kind support during my research stay in the University of Konstanz. Completing this work would have been difficult if it were not the support and friendship provided by him and the entire lab members of his group. In particular, I would like to thank Malte Sinn for his great patience in teaching me the techniques and all his support and help during my stay in Hartig group. I would also like to thank all the members of department of pharmaceutical biotechnology for their kind help and support during my PhD. My special thanks to Dr Parvin Akbarzadeh, Dr Leila Molavi and Dr Azita Dilmaghani for their kind help and encouragements during my PhD. I must express my gratitude to Dr HamidReza Heidari, my husband, for his continued support and encouragement. I was continually amazed by his endless willingness to help and support me by any means and in every aspect of our shared life. My deepest gratitude goes to my mother, father and brother for their patience and inspirations throughout my life. My sincere appreciation goes to my mother-in-law, father-in-law and sister and brothers-in-law who experienced all of the ups and downs of my research. This never-ending support of my family has been the most valuable God's blessings to me. Last but not least, I would like to express my thanks to my friends, old and new, my kind colleagues in the faculty of pharmacy, who made everything easy for me during this memorable journey. My special thanks to Dr. Vahideh Tarhriz, Dr Simin Sharifi, Dr Hamideh Mahmmodzadeh Hosseini, Dr Sanam Arami, Dr Samin Hamidi and Ms Nazanin Lakestani and all the past and current students in the Facultz of Pharmacy.. List of Publications I. Mehdizadeh Aghdam, E., A. Barzegar, and M.S. Hejazi, Evolutionary origin and conserved structural building blocks of riboswitches and ribosomal RNAs: riboswitches as probable target site for aminoglycosides interaction. GENE, In press II. Mehdizadeh Aghdam, E., A. Barzegar, and M.S. Hejazi, Evolutionary origin and conserved structural building blocks of riboswitches and ribosomal RNAs: riboswitches as probable target site for aminoglycosides interaction. Adv Pharm Bull, 1022. 2(0): p. 111-101. DOI: 2061602/apb.10226000. III. Mehdizadeh Aghdam, E., et al., Riboswitches as potential targets for aminoglycosides compared with rRNA molecules: in silico study. J Microbial Biochem Technol, 1022. 0(1). IV. Mehdizadeh Aghdam, E., et al., TPP riboswitch characterization in Alishewanella tabrizica and Alishewanella aestuarii and comparison with other TPP riboswitches. Submitted Abbreviations I Abbreviations 1D: Two dimensional 0D: Three dimensional FMN: Flavin mononucleotide GFP: Green Fluorescent Protein GlcN6P: glucosamine-6-phosphate glmS: glucosamine-6-phosphate synthetase GMP: Guanosine monophosphate HTS: High throughput screening MDR: Multiple drug resistance mRNA: messenger RNA PDB: Protein Data Bank PreQ2: Pre-queuosine 2 RMSD: Root Mean Square Deviation RNA: Ribonucleic Acid rRNA: Ribosomal RNA SAM: S-adenosylmethionine SELEX: Systematic Evolution of Ligands by Exponential Enrichment SPR: Surface Plasmon Resonance THF: Tetrahydrofuran TPP: Thiamine pyrophosphate UTR: Untranslated region Table of Contents II Table of contents Abstract 1 Chapter 1: General Introduction 2 262 INTRODUCTION ......................................................................................................................... 0 261 OBJECTIVES .............................................................................................................................. 1 260 PROJECT HYPOTHESES ................................................................................................................. 1 262 SCOPE AND OUTLINES ................................................................................................................. 6 261 REFERENCES ............................................................................................................................. 0 Chapter 2: Riboswitches: from living biosensors to novel targets of antibiotics 11 162 ABSTRACT .............................................................................................................................. 22 161 INTRODUCTION ....................................................................................................................... 21 160 HISTORY OF RIBOSWITCHES ........................................................................................................ 21 162 MECHANISMS OF RIBOSWITCHES ................................................................................................ 21 16262 glmS riboswitch/ribozyme .......................................................................................... 20 161 METHODS FOR RIBOSWITCH DISCOVERY ....................................................................................... 10 16162 In silico approaches .................................................................................................... 12 16161 Biochemical verification of riboswitch-ligand binding ............................................... 11 16160 Genetic validation of riboswitch-mediated gene regulation ...................................... 12 16162 Finding riboswitches using genome-wide mapping of transcriptional termination ... 12 166 ENGINEERED RIBOSWITCHES ...................................................................................................... 11 16662 Background ................................................................................................................ 11 16661 Riboswitch engineering .............................................................................................. 16 1666162 Selection methods............................................................................................................. 16 1.66161 Artificial Riboswitches and applications ............................................................................ 11 16660 Riboswitch-based biosensors ..................................................................................... 10 16662 Perspective ................................................................................................................. 01 161 RIBOSWITCHES AS THERAPEUTICS TARGETS ................................................................................... 01 16162 Background ................................................................................................................ 01 16161 Development of riboswitch-targeted antibiotics ....................................................... 02 1616162 Lysine riboswitch ............................................................................................................... 01 1616161 Guanine riboswitch ........................................................................................................... 01 1616160 glmS riboswitch ................................................................................................................. 01 1616162 FMN riboswitch ................................................................................................................. 00 16160 Screening of compounds ............................................................................................ 00 1616062 glmS riboswitch ................................................................................................................. 00 1616061 c-di-GMP riboswitch .......................................................................................................... 00 1616060 SAM-I riboswitch ..............................................................................................................